Podium to Practice: Chicago 2026 – LUNG: HARMONi-6 trial

Podium to Practice: Chicago 2026 – LUNG: HARMONi-6 trial

Podium to Practice: Chicago 2026

Studies / Trials Discussed

LBA4 – Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.

Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Paul Wheatley-Price

Dr. Rosalyn Juergens

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

LBA4 – Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trial.
Tagged